肿瘤细胞治疗研究
英文原题：Cancer immunotherapy in elderly patients: The concept of immune senescence challenged by clinical experience.
Cancer immunotherapy in elderly patients: The concept of immune senescence challenged by clinical experience.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
癌症免疫治疗，包括免疫检查点抑制剂、CAR-T 细胞疗法和双特异性抗体，已使多种血液系统恶性肿瘤和实体瘤的治疗取得重大进展。
癌症免疫治疗，包括免疫检查点抑制剂、CAR-T 细胞治疗和双特异性抗体，已使多种血液系统恶性肿瘤和实体瘤的治疗取得重大进展。然而，年龄介导的免疫系统改变，即免疫衰老，可能阻碍其在老年患者中的疗效。在这篇综述中，我们评估了这些不同癌症免疫治疗在老年患者中相较于年轻患者的疗效，以从治疗角度重新审视免疫衰老的概念。
Cancer immunotherapy, including immune checkpoint inhibitors, chimeric antigen receptor T-cell therapy and bispecific antibodies, has led to major improvements in the treatment of a wide range of hematologic malignancies and solid tumors. However, age-mediated immune system modifications, known as immunosenescence, may preclude its efficacy in elderly patients. In this review, we assessed the efficacy of these different cancer immunotherapies in elderly patients compared to young patients to revisit the concept of immunosenescence from a therapeutic perspective.
MEMBER ACCOUNT
登录成功会直接打开下一页。
